A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Some patients with nonproliferative diabetic retinopathy had reduced vascular leakage or macular exudation after being treated orally with danegaptide, according to a study presented at Angiogenesis, ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ...